Align Technology, Inc. (ALGN) Up 8.5% — Is This Setup Too Good to Pass Up?
Align Technology, Inc. (ALGN) is trading sharply higher this Wednesday, currently changing hands at $164.40 on the NASDAQ — up $12.82 from the prior close of $151.58. The 8.46% advance gives the clear-aligner leader one of its strongest sessions in months. Even after today's jump, ALGN sits about 18.0% below its 52-week high of $200.44, set on April 21, 2026. Investors who see this as a recovery story have meaningful room to work with if the rally holds.
Volume stands at roughly 880,528 shares with the regular session still open, already about 93% of the 90-day average of 943,629. At that pace, ALGN looks set to finish the day with above-average turnover.
Why Align Technology, Inc. Price is Moving Higher
Today's surge is part of a powerful rally across Health Care stocks. The rally followed the midterm election results, which left Democrats expected to control both chambers of Congress. Investors read that outcome as likely to limit or reverse some federal health-care cuts, and they moved quickly into medtech. The iShares U.S. Medical Devices ETF (IHI) was up 5.19% by 9:49 a.m. ET. The broader market added to the momentum, with the S&P 500 up 1.5% and the Dow up 2.6% by 11:15 a.m.
The peer moves confirm that money is flowing into the whole group. DENTSPLY SIRONA (XRAY), Align's closest dental-industry comparison, jumped 9.66%. Intuitive Surgical, Inc. (ISRG) climbed 9.75%, Stryker Corporation (SYK) added 9.30%, and Becton Dickinson (BDX) rose 4.01%. Zimmer Biomet (ZBH) surged 15.03% after it reported 3.1% year-over-year Q3 revenue growth and raised its 2026 outlook. Align's 8.46% gain puts it squarely with the leaders of this move, which shows how much upside the market was willing to price back into a name that had been heavily discounted.
The rally also builds on solid fundamentals from Align's October 28 report. Q3 adjusted EPS came in at $2.80 against a $2.76 estimate, up 7.3% year over year. Revenue reached $1.015 billion versus the $1.00 billion consensus, a 1.9% increase. The company's Q4 revenue outlook of $1.00 billion to $1.02 billion fell short of the roughly $1.05 billion Street estimate, and that cautious guide had weighed on sentiment. Today's sector-wide lift is helping the stock work through that overhang. Align also announced that Jennifer Davis will become CEO on December 31, which sets up a leadership transition heading into 2027.
What is the Align Technology, Inc. Rating - Should I Buy?
Weiss Ratings assigns ALGN a C rating. Current recommendation is Hold. The rating reflects a company with strong operating and financial foundations whose stock has not yet rewarded shareholders over the measurement period. That gap is exactly what makes today's move worth watching.
The fundamental case is the bright spot. Align is rated Excellent on both the Efficiency Index and the Solvency Index, and the latest quarter shows why the Efficiency rating holds. Adjusted EPS grew 7.3% on revenue that rose only 1.9%, so management is turning modest top-line growth into faster earnings growth. A 9.99% profit margin and a 10.16% ROE confirm that the business stays solidly profitable while it funds ongoing investment in scanners and software. The Excellent Solvency rating means the balance sheet can absorb a CEO transition and a softer near-term guide without strain. The Good rating on the Growth Index reflects 4.32% revenue growth and trailing EPS of $5.75. That growth is steady rather than spectacular, but it keeps the earnings base expanding. A forward P/E of 26.38 suggests the market still expects that growth to continue.
Where the picture becomes more nuanced is in the market-driven dimensions. ALGN is rated Weak on both the Total Return Index and the Volatility Index. A stock still trading roughly 18% below its April high has given back a meaningful share of its gains, which explains the Total Return rating. Today's 8.46% swing, driven by a policy-fueled sector rally rather than company news, shows how sharply ALGN reacts to broader health-care sentiment. That sensitivity is why the Volatility Index is not rated higher. These two dimensions hold the overall rating at C. They are also the measures most likely to improve if the current rebound gains traction.
Within the Health Care sector, Align sits alongside UnitedHealth Group Incorporated (UNH, C), Abbott Laboratories (ABT, C), Intuitive Surgical, Inc. (ISRG, C), and Stryker Corporation (SYK, C). CVS Health Corporation (CVS, C+) rates slightly higher despite falling 11.60% today. Align matches the large-cap medtech leaders on rating while trading at a much smaller $10.77B valuation, which gives patient investors an interesting comparison point.
About Align Technology, Inc.
Align Technology, Inc. (ALGN) is a Health Care company and a global pioneer in digital orthodontics. Founded in 1997 and headquartered in Tempe, Arizona, the company designs, manufactures, and markets the Invisalign system of clear aligners. Invisalign has become one of the most recognized consumer brands in dentistry, and Align has treated many millions of patients worldwide. Its aligner portfolio covers comprehensive adult treatment, teen cases, and early pediatric intervention through Invisalign First. Vivera retainers help hold results after treatment ends.
Align operates through two segments: Clear Aligner, and Imaging Systems and CAD/CAM Services. The second segment centers on the iTero line of intraoral scanners, which replace traditional impressions with digital 3D scans. iTero scanners also act as a gateway into Invisalign treatment planning. The exocad software platform extends Align's reach into restorative dentistry and dental lab workflows. Together, these products create an integrated digital ecosystem that runs from scan to treatment plan to manufactured aligner.
Align's competitive advantages come from its scale, its patient data, and its relationships with practitioners. The company sells to orthodontists, general practitioner dentists, and dental service organizations across North America, EMEA, and Asia Pacific. Its treatment-planning software is trained on an enormous base of completed cases, and few competitors can match that data advantage. Mass-customization manufacturing at high volume adds a further barrier. Every new iTero scanner placed in a practice deepens Align's ties with that clinician, which supports a durable growth flywheel in the shift from wires and brackets to clear aligners.
Investor Outlook
Align Technology (ALGN) carries a Weiss Rating of C (Hold), and today's sector-driven rally gives the stock a strong push off depressed levels. Excellent Efficiency and Solvency ratings back the business underneath that move. Investors should watch whether Q4 revenue lands at or above the top of the $1.00 billion to $1.02 billion guide, how smoothly Jennifer Davis takes over as CEO, and whether health-care policy momentum after the midterms keeps lifting the medtech group. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--